Is cognitive stimulation recommended in dementia?

Cognitive stimulation brings demonstrated benefits for cognition, communication and quality of life in people living with mild to moderate dementia. These benefits are clearer when sessions take place at least twice a week. It is among the non-pharmacological interventions recognised by France’s Haute Autorité de santé and by the World Health Organization.

What exactly do we mean

Three terms circulate and do not refer to the same thing. Cognitive training works a targeted function through repeated, calibrated exercises. Cognitive rehabilitation starts from an everyday-life goal chosen by the person and looks for the means to reach it, compensating where necessary. Cognitive stimulation, the subject here, offers group or individual activities engaging language, memory and reasoning, within a structured framework oriented towards exchange rather than towards performance.

The distinction is not academic. The results presented below concern the third and do not transfer mechanically to the other two, whose literatures are separate and whose conclusions are less convergent.

Thirty-seven trials, 2,766 participants

The review led by Woods and colleagues brings together 37 trials and 2,766 participants. It covers cognitive stimulation in people with mild to moderate dementia, most often in small groups, with regular sessions conducted over several weeks.

The most consistent benefit is observed on cognition, measured with standardised scales. The authors also find an effect on communication and on reported quality of life, two outcomes that often weigh more in a family’s daily life than the cognitive score itself. The effect remains moderate in size, and the review claims nothing about altering the course of the disease.

Woods et al., Cochrane review, 2023

Frequency weighs on the result

The parameter that stands out most clearly from comparisons between protocols is the rhythm. Benefits are more marked when sessions are held at least twice a week, which echoes, in an entirely different clinical field, what the aphasia literature establishes about intensity.

This point deserves attention because it is rarely the first to be adjusted. Faced with constrained resources, a service more readily reduces frequency than the total duration of care, whereas frequency is the variable these trials document.

The same logic appears in a neighbouring clinical field. In aphasia rehabilitation, trials reach a conclusion of the same shape: for an equal volume, concentrating sessions matters more than spreading them out. Two independent literatures converging on this point deserve to be read together, without concluding that a common mechanism explains them. See intensity in aphasia rehabilitation.

Mild cognitive impairment, a stage apart

The Cochrane review concerns established dementia. Upstream lies mild cognitive impairment, a stage at which learning capacities remain largely available and where training therefore has the greatest margin. It is also the stage at which the fewest people receive structured follow-up.

The status of this observation needs stating precisely: it is consistent with the data, it is not demonstrated by them. The Woods review does not cover this stage, and we do not have an equivalent body of evidence here to assert it.

Two reference texts, two scopes

The World Health Organization guidelines published in 2019 on reducing the risk of cognitive decline retain cognitive training among the interventions to be offered. In France, the Haute Autorité de santé lists cognitive stimulation among the non-pharmacological interventions recognised in the management of neurocognitive disorders.

These two texts do not have the same scope. The World Health Organization guidelines deal with risk reduction in the general population, in people who do not yet present an established disorder. The positions of the Haute Autorité de santé concern management once the diagnosis has been made. Citing them together is common, and it is better to know that they answer two distinct questions.

Demographic pressure gives them concrete weight. The Swiss Federal Statistical Office scenarios for 2025-2055 describe a markedly older Swiss population, hence a growing number of people concerned, without a proportional increase in the number of clinicians. A frequency recommendation issued in this context immediately raises a question of organisation: how to sustain two weekly sessions per person when the number of people grows faster than the number of professionals.

What this implies day to day

Two practical consequences emerge. The first is that regularity outweighs the length of each session: two short appointments are better than one long one, if we follow what these trials document. The second is that the material must remain accessible to the person, which calls for brief instructions, a pace the person controls and activities that do not put failure on display.

This second requirement is harder to meet than it seems. An activity that is too simple is perceived as infantilising and is paid for in rapid disengagement; one that is too demanding installs the very sense of loss one was seeking to avoid. The margin is narrow, it shifts as the disease progresses, and it therefore needs to be readjusted often rather than set once.

A third consequence concerns those around the person. In the group trials, part of the arrangement rests on the presence of others. When the work continues at home, that role falls in practice to a relative, who has neither the training nor the distance of a professional. Giving them a clear instruction on what to do, and above all on what is not theirs to do, is part of the care.

To this is added a question of format. Most of the included trials concern group sessions, where part of the effect probably owes as much to the exchange itself as to the activities. Individual work at home does not reproduce this component, and that needs to be known before transposing the results to that setting.

One limitation, finally, that it would be dishonest to pass over in silence: these benefits are measured during the intervention period. What persists after it stops is far less documented. The review allows us neither to assert that the effect is maintained, nor to say that it disappears, and this uncertainty bears on what matters most to a family.

How doMind puts this into practice

doMind lets the clinician compose graded series of activities, workable in the session as at home, and renew them without starting from scratch. This ability to sustain a steady rhythm without multiplying preparation time is what brings practice closer to the frequencies described in these trials. Discover the tool.

Book a demonstration

Sources

  1. Woods et al., Cochrane review, 2023 · 37 trials, 2,766 participants
    doi.org/10.1002/14651858.CD005562.pub3
  2. World Health Organization, Risk reduction of cognitive decline and dementia: WHO guidelines, 2019.
  3. Haute Autorité de santé, non-pharmacological interventions in neurocognitive disorders.
  4. Swiss Federal Statistical Office, scenarios for Switzerland’s population 2025-2055; Song et al., 2023.

These pages report the literature. They do not constitute a therapeutic recommendation.